By Jonathan Gardner | Published August 20, 2026
In a significant development for the rare disease community, the therapeutic landscape for Fibrodysplasia Ossificans Progressiva (FOP)—a debilitating condition characterized by the transformation of soft tissue into bone—has shifted dramatically. The approval of Regeneron’s Pasatru (garetosmab) marks a pivotal moment for patients suffering from this ultra-rare, progressive disorder. As the medical community celebrates this milestone, the drug’s entry sets the stage for a high-stakes commercial battle against Ipsen’s Sohonos, the only other FDA-approved treatment for the condition.
Main Facts: A New Tool Against Bone Formation
Pasatru, known scientifically as garetosmab, represents a novel approach to managing FOP. Unlike previous attempts at treatment, Pasatru functions as a monoclonal antibody specifically designed to inhibit Activin A. In patients with FOP, this protein is a primary driver of the inflammatory "flare-ups" that lead to heterotopic ossification—the process where muscle, tendons, and ligaments turn into bone.
The drug’s approval is backed by clinical data suggesting it can intercept the pathological signaling pathway that creates these bone growths. However, with its arrival comes a staggering price tag. Regeneron has announced an average annual list price of approximately $1.4 million per patient. Given the flexible dosing regimen—which ranges from 3 mg to 10 mg per kilogram of body weight—the actual cost to the healthcare system could fluctuate between $693,000 and $2.1 million per patient annually, depending on individual clinical requirements.
Chronology: The Road to Approval and Market Entry
The journey to this moment has been long and fraught with scientific challenges. FOP is notoriously difficult to study due to the extremely small patient population and the complexity of its progression.
- Pre-2023: Research into Activin A inhibition gained momentum, with Regeneron positioning garetosmab as a potential disease-modifying therapy.
- August 2023: The FDA granted approval to Ipsen’s Sohonos (palovarotene), the first drug indicated for the reduction of new heterotopic ossification in adults and children with FOP. However, the launch was marred by concerns regarding efficacy and safety profiles.
- 2024: Ipsen faced significant commercial headwinds, ultimately recording an impairment charge of 279 million euros due to slower-than-anticipated market penetration.
- August 20, 2026: Regeneron secures FDA approval for Pasatru, introducing a direct competitor into the limited FOP market.
- Late 2026 and Beyond: The focus shifts to market access, physician adoption, and the comparative performance of Pasatru versus the incumbent treatment.
Supporting Data: Comparing the Therapeutic Options
The arrival of Pasatru forces a comparison between two distinct therapeutic strategies. While head-to-head clinical trials have not been conducted, the existing data packages provide a basis for clinical decision-making.
Ipsen’s Sohonos has struggled to capture market confidence. During its approval process, FDA scientists noted concerns that patients on the drug might experience a higher incidence of the very inflammatory flare-ups that trigger bone growth. Furthermore, clinical data indicated a more modest impact on preventing ossification compared to what patient advocacy groups initially hoped for.
In contrast, Pasatru’s mechanism of action—targeting the protein directly responsible for triggering the ossification cascade—is viewed by many researchers as more precise. By blocking Activin A, Regeneron aims to prevent the biological "signal" that tells the body to begin turning soft tissue into bone, potentially offering a more robust defense against the disease’s progression.
Official Responses: The Patient Perspective
For the patient community, the arrival of a new, highly effective option is nothing short of transformative. Michelle Davis, executive director of the International FOP Association, issued a statement praising the approval.
"This approval is monumental for our community, providing a vital new therapy that can have a significant impact on the life of someone with FOP," Davis said. "For families who have been living with limited options and the constant fear of sudden, irreversible bone growth, having an additional tool in our arsenal is a beacon of hope."
The sentiment reflects a broader desire within the rare disease space for therapies that don’t just manage symptoms but address the underlying molecular drivers of a condition.
Implications: A Strategic Crossroads for Regeneron
The launch of Pasatru occurs at a critical juncture for Regeneron. The company is currently navigating a period of transition as it faces mounting pressure on its core franchise.
1. The Eylea Challenge:
Regeneron’s primary revenue engine, the eye drug Eylea, is beginning to feel the heat from a wave of biosimilar competition. While the company has attempted to pivot to a high-dose version of the drug, initial sales performance has not met the aggressive expectations set by some market analysts.
2. R&D Setbacks:
The company’s broader pipeline has also seen recent volatility. An up-and-coming cancer immunotherapy candidate, which was expected to be a major growth driver, recently missed its primary endpoint in a key clinical trial. This failure has placed even greater emphasis on the successful commercialization of specialty drugs like Pasatru.
3. Market Competition:
Ipsen’s commercial struggle with Sohonos—evidenced by the 21 million euros in revenue reported for the first half of 2026—serves as a cautionary tale. The FOP market is small, and the high cost of these therapies invites intense scrutiny from insurers and pharmacy benefit managers. Regeneron must now demonstrate that the clinical value of Pasatru justifies its seven-figure price point in a way that its predecessor could not.
4. The Future of Rare Disease Pricing:
The pricing of Pasatru is likely to reignite debates regarding the cost of orphan drugs. While proponents argue that the high cost is necessary to recoup the massive investment required to research and develop treatments for extremely rare populations, critics point to the burden on public and private health insurance systems. The success of Pasatru will be measured not only by its clinical efficacy but by its ability to secure broad coverage and reimbursement in a cost-conscious environment.
Looking Ahead
As Pasatru hits the market, the medical community will be watching closely to see how quickly it can gain traction among specialists. With the disease being so rare, every patient transition or new prescription will be a significant data point in the ongoing assessment of the drug’s real-world utility.
For Regeneron, Pasatru is more than just a new product; it is a test of the company’s ability to successfully navigate the complex regulatory and commercial dynamics of the rare disease space. As the company attempts to diversify its portfolio away from its reliance on eye care, the performance of its newest, most expensive, and most specialized drug will be a critical indicator of its long-term health in an evolving pharmaceutical industry.
Ultimately, the competition between Pasatru and Sohonos will likely hinge on safety, durability of effect, and the strength of the clinical data as it emerges from real-world use. For the FOP community, the existence of this competition is a welcome development, as it guarantees that the focus remains on innovation and the pursuit of a better quality of life for those living with this rare and challenging condition.
About the Author
